Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00
Provider: S&P Capital IQ – STARS Reports
$127.00
Provider: Reuters Investment Profile
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Slater & Gordon Ltd resolves Thalidomide class actions with Diageo PLC


Sunday, 1 Dec 2013 06:48pm EST 

Slater & Gordon Ltd:Says that two representative proceedings for Australian and New Zealand victims of the drug Thalidomide have been resolved with Diageo PLC.Says has been conducting the class actions, in a joint venture with Gordon Legal, since 2010 on a No Win No Fee basis.Says the settlement will have no material impact on Slater & Gordon’s net earnings. 

Company Quote

1876.094
 --
26 Nov 2014